When Prof. James P. Allison and his group initially introduced the anti-CTLA-4 blockade to reinvigorate anti-tumour T cells to fight solid tumours, the therapeutic effect of this breakthrough was only achieved in the context of tumours with preserved immunogenicity (hot tumours) [22, 23]. The gene discussed is CTLA4; the disease is neoplasm.